Skip to main content
SpringerLink
Log in

Combined chemotherapy plus radiotherapy for treatment of earlystage intermediate- and high-grade non-Hodgkin’s lymphoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Treatment of localized (stages I, IE, non-bulky II and IIE) aggressive histologies of non-Hodgkin’s lymphoma has evolved over the past 20 years. Prior to 1980, these diseases were shown to be locally controlled with radiotherapy, but systemic relapse and death were common. With the discovery of potentially curative doxorubicin-containing chemotherapy, pilot studies during the 1980s demonstrated the utility of combination chemotherapy as initial therapy by increasing the proportion of cured patients. In the 1990s, two large randomized, prospective trials set the benchmark for future comparisons by establishing initial chemotherapy followed by radiation therapy (combined modality therapy) as the best available current treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Shipp MA, Harrington DP: A predictive model for aggressive non-Hodgkin’s lymphoma: the International NHL Prognostic Factor Project. N Engl J Med 1993, 329:987–994.

    Article  Google Scholar 

  2. Romaguera JE, Velasquez WS, Silvermintz KB, et al.: Surgical debulking is associated with improved survival in Stage I-II diffuse large cell lymphoma. Cancer 1990, 66:267–272.

    Article  Google Scholar 

  3. Aref A, Narayan S, Tekyi-Mensah S, et al.: Value of radiation therapy in the management of chemoresistant intermediate grade non-Hodgkin’s lymphoma. Radiat Oncol Investig 1999, 7:186–191.

    Article  PubMed  CAS  Google Scholar 

  4. Glick JH, Kim K, Earle J, O’Connell MJ: An ECOG randomized phase III trial of CHOP vs. CHOP plus radiotherapy for intermediate grade early stage non-Hodgkin’s lyphoma[abstract]. Proc ASCO 1995, 14:391a. This phase III ECOG trial demonstrates the benefit of the addition of involved-field radiotherapy in patients with bulky and extranodal stage I and stage II intermediate-grade lymphomas receiving CHOP chemotherapy. Patients receiving the combined modality approach had significantly improved disease-free survival and failure-free survival, whereas overall survival rates approached a significant improvement.

    Google Scholar 

  5. Fuller LM, Krasin MJ, Velasquez WS, et al.: Significance of tumor size and radiation dose to local control in stage I-III diffuse large cell lymphoma treated with CHOP-bleomycin and radiation. Int J Radiat Oncol Biol Phys 1995, 31:3–11.

    Article  PubMed  CAS  Google Scholar 

  6. Bagley CM, DeVita VT, Berard C, et al.: Advanced lymphosarcoma: intensive combination chemotherapy with cyclophosphamide, vincristine and prednisone. Ann Intern Med 1972, 76:227–234.

    PubMed  Google Scholar 

  7. McKelvey EM, Gottlieb JA, Wilson HE, et al.: Hodroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976, 38:1484–1493.

    Article  PubMed  CAS  Google Scholar 

  8. Hoskins PJ, Ng V, Spinelli JJ, et al.: Prognostic variables in patients with diffuse large cell lymphoma treated with MACOP-B. J Clin Oncol 1991, 9:220–226.

    PubMed  CAS  Google Scholar 

  9. Longo DL, DeVita VT, Duffey PL, et al.: Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991, 9:25–38.

    PubMed  CAS  Google Scholar 

  10. Coleman M, Armitage JO, Gaynor M, et al.: The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988,(suppl) 25:23–33.

    PubMed  CAS  Google Scholar 

  11. Coiffier B, Gisselbrecht C, Herbrecht R, et al.: LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989, 7:1018–1026.

    PubMed  CAS  Google Scholar 

  12. Fisher R, Gaynor E, Dohlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced NHL. NEJM 1993, 328:1002–1006. This SWOG trial convincingly demonstrates CHOP chemotherapy as the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin’s lymphoma. Patients receiving the CHOP regimen had the same response rates and overall survival, but with a lower incidence of fatal toxicities, when compared with second- and third-generation regimens.

    Article  PubMed  CAS  Google Scholar 

  13. Vokes EE, Ultmann JE, Golomb HM: Long-term survival of patients with localized diffuse histiocytic lymphoma. J Clin Oncol 1985, 3:1309–1317.

    PubMed  CAS  Google Scholar 

  14. Bitran JD, Kinzie J, Sweet DL, et al.: Survival of patients with localized histiocytic lymphoma. Cancer 1977, 39:342–346.

    Article  PubMed  CAS  Google Scholar 

  15. Kaminski MS, Coleman CN, Colby TV: Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiotherapy. Ann Intern Med 1986, 104:747–756.

    PubMed  CAS  Google Scholar 

  16. Longo DL, Hathorn J: Current therapy for diffuse large-cell lymphoma. Prog Hematol 1987, 14:115–136.

    Google Scholar 

  17. Jones SE, Fuks Z, Kaplan HS, et al.: Non-Hodgkin’s lymphoma. V. Results of radiotherapy. Cancer 1973, 32:682–687.

    Article  PubMed  CAS  Google Scholar 

  18. Sutcliffe SB, Gaspodarowicz MK, Bush RS, et al.: Role of radiation therapy in localized non-Hodgkin’s lymphoma. Radiother Oncol 1985, 4:211–223.

    Article  PubMed  CAS  Google Scholar 

  19. Jones SE, Miller TP, Connors JM: Long term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989, 7:1186–1191.

    PubMed  CAS  Google Scholar 

  20. Cabanillas F, Bodey GP, Freireich EJ: Management with chemotherapy only of stage I and II malignant lymphoma of aggressive histologic types. Cancer 1980, 46:2356–2359.

    Article  PubMed  CAS  Google Scholar 

  21. Jeffrey GM, Mead GM, Whitehoue JMA, et al.: Involved field radiotherapy or chemotherapy in the management of Stage I nodal intermediate grade non-Hodgkin’s lymphoma. Br J Cancer 1991, 64:933–937.

    Google Scholar 

  22. Landberg TG, Hakansson LG, Moller TR, et al.: CVP-remissionmaintenance in stage I or II non-Hodgkin’s lymphoma. Cancer 1979, 44:831–838.

    Article  PubMed  CAS  Google Scholar 

  23. Monfardini S, Banfi A, Bonadonna G, et al.: Improved five year survival after combined radiotherapy and chemotherapy for stage I-II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 1980, 6:125–134.

    PubMed  CAS  Google Scholar 

  24. Nissen NI, Ersboll J, Hansen HS, et al.: A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin’s lymphoma. Cancer 1983, 52:1–7.

    Article  PubMed  CAS  Google Scholar 

  25. Mauch P, Leonard R, Skarin A, et al.: Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin’s lymphoma. J Clin Oncol 1985, 3:1301–1308.

    PubMed  CAS  Google Scholar 

  26. Bajetta E, Valagussa P, Bonadonna G, et al.: Combined modality treatment for stage I-II non-Hodgkin’s lymphoma: CVP versus BACOP chemotherapy. Int J Radiat Oncol Biol Phys 1988, 15:3–12.

    PubMed  CAS  Google Scholar 

  27. Ibrahim EM, Satti MB, Al-Idrissi HY, et al.: Combination chemotherapy only for stage II non-Hodgkin’s lymphoma. Eur J Cancer Clin Oncol 1986, 22:199–203.

    Article  PubMed  CAS  Google Scholar 

  28. O’Connel MJ, Harrington DP, et al.: Chemotherapy followed by consolidation radiation therapy for the treatment of clinical stage II aggressive histologic type non-Hodgkin’s lymphoma. Cancer 1988, 61:1754–1758.

    Article  Google Scholar 

  29. Connors JM, Klimo P, Fairey RN, et al.: Brief Chemotherapy and involved field radiation therapy for limited stage, histologically aggressive lymphoma. Ann Intern Med 1987, 107:25–30.

    PubMed  CAS  Google Scholar 

  30. Longo DL, Glatstein E, Duffey P, et al.: Treatment of localized aggressive lymphomas: combination chemotherapy followed by involved field radiation therapy. J Clin Oncol 1989, 7:1295–1302.

    PubMed  CAS  Google Scholar 

  31. Tondini C, Zanini M, Lombardi F, et al.: Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin’s Lymphomas. J Clin Oncol 1993, 11:720–725.

    PubMed  CAS  Google Scholar 

  32. Villikka K, Muhonen T, Ristamaki R, et al.: Stage I non-Hodgkin’s lymphoma treated with doxorubicin-containing chemotherapy with or without radiotherapy. Acta Oncol 1997, 36:619–624.

    PubMed  CAS  Google Scholar 

  33. Freilone BB, Vitolo U, Bertini M, et al.: Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate to high-grade non-Hodgkin’s lymphoma. Ann Oncol 1996, 7:919–924.

    PubMed  CAS  Google Scholar 

  34. Munck JN, Dhermain F, Koscielny S, et al.: Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin’s lymphomas: long-term results for 96 patients with tumors >5 cm. Ann Oncol 1996, 7:925–931.

    PubMed  CAS  Google Scholar 

  35. van der Maazen RW, Noordijk EM, Raemaekers JM, Meerwaldt JH. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high-grade non-Hodgkin’s lymphomas. Radiother Oncol 1998, 49:1–7. This retrospective multi-institutional report comparing radiation therapy alone to CMT (chemotherapy followed by involved-field radiation therapy) in stage I/IE NHL demonstrates improved diseasefree and overall survival rates for patients receiving the combined approach. Recurrences were seen within 4 years of CMT, whereas recurrences were seen up to 10 years after radiation alone.

    Article  PubMed  Google Scholar 

  36. Osterman B, Cavallin-Stahl E, Hagberg H, et al.: High Grade Non-Hodgkin’s Lymphoma Stage I. Acta Oncol 1996, 35:171–177.

    PubMed  CAS  Google Scholar 

  37. Kamath SS, Marcus RB, Lynch JW, Mendenhall NP: The impact of radiotherapy dose and other treatment related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 1999, 44:563–568. This single-institution report examines the impact of radiation dose and failure patterns in patients receiving therapy for NHL. This study suggests that, in intermediate- and high-grade NHL, failure outside of the radiation field is common when RT alone is used. Radiation doses greater than 40 Gy may be necessary for better local control in this subset of patients.

    Article  PubMed  CAS  Google Scholar 

  38. Ferreri AJ, Reni M, Ceresoli GL, et al.: Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin’s lymphoma of bone in adults. Cancer Invest 1998, 16:554–561.

    PubMed  CAS  Google Scholar 

  39. Pasini F, Cetto GL, Todeschini G, et al.: Combination of chemotherapy and radiotherapy improves the cure rate in primary extranodal lymphomas of the head and neck (PLHN). Anticancer Res 1997, 17:2837–2842.

    PubMed  CAS  Google Scholar 

  40. Nathu RM, Mendenhall NP, et al.: Non-Hodgkin’s lymphoma of the head and neck: a 30-year experience at the University of Florida. Head Neck 1999, 21:247–254. This retrospective review of intermediate- and high-grade stage I and II NHL of the head and neck regions suggests that patients treated with combined modality therapy fare better than those receiving radiotherapy alone. Tumor size was an important factor for prognosis.

    Article  PubMed  CAS  Google Scholar 

  41. Donato V, Iacari V, Aurlo A, et al.: Radiation therapy and chemotherapy in the treatment of head and neck extranodal non-Hodgkin’s lymphoma in early stage with a high grade of malignancy. Anticancer Res 1998, 18:547–554. This study retrospectively compares the therapy and outcome of patients with early-stage intermediate- and high-grade lymphoma. Although not statistically significant, patients receiving combined modality attained improved overall and disease-free survival rates, with less toxicity.

    PubMed  CAS  Google Scholar 

  42. Miller TP, Dahlberg S, Cassady JR, et al.: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998, 339:21–26. This SWOG randomized trial comparing a standard course of chemotherapy alone with a combined modality regimen (chemotherapy followed by radiation therapy) demonstrates a significantly improved progression-free survival and overall survival for the CMT arm. There were fewer toxic events in the chemotherapy plus radiotherapy arm.

    Article  PubMed  CAS  Google Scholar 

  43. Wylie JP, Cowan RA, Deakin DP: The role of radiotherapy in the treatment of the localized intermediate and high-grade non-Hodgkin’s lymphoma in elderly patients. Radiother Oncol 1998, 49:9–14.

    Article  PubMed  CAS  Google Scholar 

  44. Oguchi M, Izuno I, Taki K, et al.: Treatment for Non-Hodgkin’s lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy. Int J Radiat Oncol Biol Phys 1997, 37:87–92. This prospective trial examines the use of local/regional radiation therapy with reduced-dose chemotherapy in elderly patients. Its results demonstrate the effectiveness of reduced-dose doxorubicinbased chemotherapy in the elderly with favorable control and survival rates, and a low rate of toxicity.

    Article  PubMed  CAS  Google Scholar 

  45. Miller TP, Jones SE: Is there a role for radiotherapy in localized diffuse lymphomas. Cancer Chemother Pharmacol 1980, 4:67–70.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Radiation Oncology and Medicine, Arizona Cancer Center, University of Arizona, 1515 North Campbell Avenue, 85724, Tucson, AZ, USA

    Jonathan H. Briggs MD & Thomas P. Miller MD

Authors
  1. Jonathan H. Briggs MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas P. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Briggs, J.H., Miller, T.P. Combined chemotherapy plus radiotherapy for treatment of earlystage intermediate- and high-grade non-Hodgkin’s lymphoma. Curr Oncol Rep 2, 176–181 (2000). https://doi.org/10.1007/s11912-000-0091-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-000-0091-z

Keywords

Search

Navigation